Table 1.
The Cancer Genome Atlas (TCGA) ovarian serous cystadenocarcinoma (OVs) patient characteristics.
| Characteristics | Number of cases | Percentages |
|---|---|---|
| Clinical stage | ||
| Stage I | 1 | 0.27 |
| Stage II | 22 | 5.9 |
| Stage III | 293 | 78.55 |
| Stage IV | 57 | 15.28 |
| Primary therapy outcome | ||
| SD | 22 | 7.28 |
| PD | 27 | 8.94 |
| PR | 43 | 14.24 |
| CR | 210 | 69.54 |
| OS | ||
| Alive | 146 | 38.83 |
| Dead | 230 | 61.17 |
| Cancer status | ||
| Tumor free | 85 | 25.68 |
| With tumor | 246 | 74.32 |
| Histologic grade | ||
| G1 | 1 | 0.27 |
| G2 | 42 | 11.48 |
| G3 | 322 | 87.98 |
| G4 | 1 | 0.27 |
| Tumor residual disease | ||
| NRD | 66 | 19.82 |
| RD | 267 | 80.18 |
| Anatomic neoplasm subdivision | ||
| Unilateral | 101 | 28.53 |
| Bilateral | 253 | 71.47 |
| Age | ||
| <60 | 198 | 52.66 |
| ≥60 | 178 | 47.34 |
SD: stable disease; PD: progressive disease; PR: partial remission; CR: complete remission; OS: overall survival; NRD: no residual disease; RD: residual disease.